Stoke Therapeutics reported a quarterly loss of $0.79 per share, slightly better than the Zacks Consensus Estimate for a $0.80 loss. That compares with earnings of $1.90 per share a year ago, indicating a sharp year-over-year deterioration despite the small earnings beat versus expectations.
Stoke Therapeutics reported a quarterly loss of $0.79 per share, slightly better than the Zacks Consensus Estimate for a $0.80 loss. That compares with earnings of $1.90 per share a year ago, indicating a sharp year-over-year deterioration despite the small earnings beat versus expectations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
-0.05
Ticker Sentiment
